Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1758-9193

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume ; volume:11 ; number:1 ; day:26 ; month:12 ; year:2019 ; pages:1-10 ; date:12.2019
Alzheimer's research & therapy ; 11, Heft 1 (26.12.2019), 1-10, 12.2019

Creator: Caldwell, Jessica Z. K.
Cummings, Jeffrey L.
Banks, Sarah J.
Palmqvist, Sebastian
Hansson, Oskar

Contributor: SpringerLink (Online service)

DOI: 10.1186/s13195-019-0565-1

URN: urn:nbn:de:101:1-2020041514280050780269

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 14.08.2025, 10:50 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Caldwell, Jessica Z. K.
Cummings, Jeffrey L.
Banks, Sarah J.
Palmqvist, Sebastian
Hansson, Oskar
SpringerLink (Online service)

Other Objects (12)

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Blood‐based biomarkers for Alzheimer's disease

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer’s dementia

Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Blood‐based biomarkers for Alzheimer's disease

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer’s dementia

Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Blood‐based biomarkers for Alzheimer's disease

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer’s dementia

Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Blood‐based biomarkers for Alzheimer's disease

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer’s dementia

Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Blood‐based biomarkers for Alzheimer's disease

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer’s dementia

Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum

Antibodies against phosphorylcholine are not altered in plasma of patients with Alzheimer’s disease

Fluid biomarkers in Alzheimer’s disease – current concepts

Cerebro-spinal fluid biomarker levels: phosphorylated tau (T) and total tau (N) as markers for rate of progression in Alzheimer’s disease

Changes in cerebrospinal fluid and blood plasma levels of IGF-II and its binding proteins in Alzheimer’s disease: an observational study

Blood‐based biomarkers for Alzheimer's disease

[18F]Flortaucipir distinguishes Alzheimer’s disease from progressive supranuclear palsy pathology in a mixed-pathology case

Cerebrospinal fluid soluble TREM2 in aging and Alzheimer’s disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease

Alpha-amylase 1A copy number variants and the association with memory performance and Alzheimer’s dementia

Alterations of matrix metalloproteinases in the healthy elderly with increased risk of prodromal Alzheimer's disease

Tau-related grey matter network breakdown across the Alzheimer’s disease continuum

Related objects

Reset password